InspireMD grants 91,161 restricted shares to new employees

InspireMD, Inc. has granted an aggregate of 91,161 shares of restricted stock to six new non-executive employees as an inducement material to their employment. The grants were approved by the Compensation Committee of InspireMD's Board of Directors with a grant date of June 12, 2026.

The Inducement Grants were issued outside of InspireMD's 2021 Equity Incentive Plan and were instead granted under the InspireMD's 2024 Inducement Plan. This plan is used exclusively for equity awards to individuals who were not previously employees of the company, or following a bona fide period of non-employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock vests over a three-year period. One-third of the shares vest on the first anniversary of the grant date, with the remainder vesting in two equal installments on the second and third anniversaries. All vesting is subject to the continued employment of the recipients with InspireMD as of the applicable vesting dates.

Grant Details

Detail	Information
Total Shares Granted	91,161
Recipients	6 new non-executive employees
Grant Date	June 12, 2026
Vesting Period	3 years
Governing Plan	2024 Inducement Plan

InspireMD develops the CGuard Prime carotid stent system for the prevention of stroke and its common stock is quoted on Nasdaq under the ticker symbol NSPR.

InspireMD, Inc. announced positive 30-day outcomes from the CGUARDIANS II clinical trial evaluating the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. The trial demonstrated 100% acute device success with no reported deaths, strokes, or myocardial infarctions within the 30-day period. The company anticipates potential approval of the CGuard Prime 80cm stent implant in the second half of this year.

Key Trial Outcomes

The CGUARDIANS II trial evaluated the safety and performance of the CGuard Prime 80cm implant. The primary focus was on acute device success and the absence of major adverse events within the first month post-procedure.

Metric	Outcome
Acute device success	100% (50/50 patients)
Deaths, strokes, or myocardial infarctions (30 days)	0
Stent thrombosis (30 days)	0
Complete stent patency (30 days)	Observed in evaluable subjects

The absence of stent thrombosis and the observation of complete stent patency in evaluable subjects further support the safety profile of the device. These results are critical for the company's regulatory submission and anticipated approval timeline.